中国动脉硬化杂志2012，Vol.20Issue(4)：380-384,5.
前蛋白转化酶枯草溶菌素9基因多态性的临床研究进展
Clinical Advance of PCSK9 Polymorphism
摘要
Abstract
Proprotein convertase suhtilisin/kexin type 9 (PCSK9) is closely related to modulate plasma cholesterol metabolism as newly discovered, and belongs to the proprotein convertase (PC) family. PCSK9 is a protein that reduces risk of coronary artery disease, peripheral vascular disease, cerebrovascular disease, nervous system diseases and diabetes by lowering serum low density Iipoprotein cholesterol ( LDLC) levels. Recent studies have shown that PCSK9 polymorphisms may modulate plasma cholesterol levels either positively or negatively. Recognition of these polymorphisms may have clinical significance in assessing severity of disease, prognosis, or response to drug therapy. This review focuses on recent advances of the influence of PCSK9 polymorphisms on LDLC and clinical advance of PCSK9.关键词
前蛋白转化酶枯草溶菌素9/低密度脂蛋白胆固醇/胆固醇代谢/冠状动脉粥样硬化性心脏病/糖尿病Key words
Proprotein Convertase Subtilisin/Kexin Type 9/Low Density Iipoprotein Cholesterol/Cholesterol Metabolism/Coronary Artery Disease/Diabetes分类
医药卫生引用本文复制引用
龚慧琴,吴琪,文红艳,刘录山..前蛋白转化酶枯草溶菌素9基因多态性的临床研究进展[J].中国动脉硬化杂志,2012,20(4):380-384,5.基金项目
国家自然科学基金(30700325)、湖南省教育厅重点项目(10A105)、湖南省科技厅项目(2010TP4008-2)和湖南省高校科技创新团队支持计划 （30700325）
